<DOC>
	<DOCNO>NCT01815580</DOCNO>
	<brief_summary>This study recruit men transgender woman acute recent HIV infection . It wil look HIV medicine ( ART ) give early HIV infection affect amount HIV blood , semen rectal secretion . In addition , Investigators use model study look whether kind HIV treatment decrease risk man infect person sex find failure take medication impact spread virus people . In study , one group randomize ( like coin toss ) start ART immediately ( time enrollment visit ) group wait week 24 study start ART . Both group follow total 48 week continue receive ART local source study .</brief_summary>
	<brief_title>HIV Test Treat Prevent HIV Transmission Among MSM Transgender Women</brief_title>
	<detailed_description>This three-step study . Step 1 screen men sex men ( MSM ) transgender woman unaware HIV status 1 ) report high risk behavior acquire HIV-1 infection 2 ) symptom acute retroviral syndrome 3 ) sexual partner newly-diagnosed acute recent HIV infection . HIV test conduct several thousand MSM transgender woman study open July 2015 . In Step 2 , high risk HIV-1 uninfected MSM transgender woman high risk acquire HIV test regular interval incident HIV-1 ( use test HIV p24 and/or HIV RNA ) . ( During period , men receive standard HIV prevention intervention . ) In Step 3 , individual acute recent HIV-1 infection enrol 48-week randomized , open-label study effect immediate vs. defer ART decay dynamic HIV viral load plasma , semen rectal secretion . ( ART provide prior 24 week participant defer ART arm meet initiation criterion . ) All participant follow 48 week continue ART source .</detailed_description>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Adult men sex men , transgender woman Unaware HIV status enrollment followup cohort High risk HIV infection Willing test HIV No prior ART , include prior administration pre postexposure prophylaxis last 30 day Willing provide inform consent Prior receipt investigational antiHIV vaccine Ongoing therapy follow : 1 . Systemic corticosteroid . Short course less equal 21 day corticosteroid allow 2 . Systemic chemotherapeutic agent 3 . Nephrotoxic systemic agent , include aminoglycosides , amphotericin B , cidofovir , cisplatin , foscarnet , pentamidine 4 . Immunomodulatory treatment include Interleukin2 5 . Investigational agent Known allergy/sensitivity hypersensitivity component study drug ( ART ) formulation Active drug alcohol use dependence would interfere adherence study requirement Serious medical psychiatric illness would interfere ability adhere study requirement Chronic acute hepatitis B infection Use female hormonal product base estrogen derivative</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>Treatment Prevention</keyword>
	<keyword>Seek , Test , Treat , Retain Strategies</keyword>
</DOC>